Biotechnology Medical Technology Regulations 
Bill Of Health
OCTOBER 17, 2023
Regenerative medical technologies use cell- and tissue-based methods to recapitulate, bioengineer, and reprogram human tissue, making a whole suite of sci-fi-sounding technologies an ever-closer reality. It seems, in the near term, that the “who” would probably be a venture-backed biotechnology company — a corporate actor.
Bill Of Health
MAY 20, 2024
This includes addressing potential specific AI-related risks—such as biases, discrimination, and data poisoning—as well as ensuring data security and privacy, and delineating liability for failures or harm caused by these technologies. Each application requires a tailored approach, integrating various standards to address specific needs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill Of Health
OCTOBER 27, 2023
The HIPAA Problem The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters. The innovation-security tradeoff is a familiar trope in biotechnology, but the main character of the direct-to-consumer tissue-based service story is less so.
Bill Of Health
MARCH 23, 2023
By Enrique Santamaría Together with the Data Governance Act (DGA) and the General Data Protection Regulation (GDPR), the proposal for a Regulation on the European Health Data Space (EHDS) will most likely form the new regulatory and governance framework for the use of health data in the European Union. health data). If so, how?
Bill Of Health
SEPTEMBER 22, 2022
These five students are a fantastic cohort of health law policy, biotechnology, and bioethics scholars who join us from across Harvard. She has previously published articles on synthetic biology regulation and governance, end stage renal disease payment reform, and comparative analyses of learning disorder policy.
Bill Of Health
NOVEMBER 10, 2022
Trust and Design : Looking closely at data protection issues with a particular emphasis on questions of consent and trust in the context of the new data that is created by medical technologies.
Bill Of Health
SEPTEMBER 16, 2024
She is interested in mass torts, drug product liability, pharmaceutical antitrust, and the administrative law that affects health-related regulations promulgated by agencies. 2026) research interests include innovative medical technologies and chronic disease policy. Rupa Palanki’s (J.D. Jessica Samuels (J.D./MPH
Expert insights. Personalized for you.
113 
Let's personalize your content